Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary Vein Isolation: Patient Experience under Conscious Sedation versus Anaesthesia.

Irish medical journal·2026
Same author

Where do we go from here? The personal impact of adverse events and complications in surgeons: Results from a cross-sectional study.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2025
Same author

Cardiovascular risk assessment for osteoporosis patients considering Romosozumab.

Bone·2024
Same author

Uncertainty in low back pain care - insights from an ethnographic study.

Disability and rehabilitation·2022
Same author

Comparing traditional modeling approaches versus predictive analytics methods for predicting multiple sclerosis relapse.

Multiple sclerosis and related disorders·2022
Same author

The toxic cutaneous effects of Gamma Butyrolactone (GBL).

Burns : journal of the International Society for Burn Injuries·2021

Related Experiment Video

Updated: Jul 25, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Local gene delivery to the vessel wall.

R C Smith1, K Walsh

  • 1Division of Cardiovascular Research, St Elizabeth's Medical Center, Boston, MA 02135, USA.

Acta Physiologica Scandinavica
|October 27, 2001
PubMed
Summary

This review covers vascular gene therapy delivery methods proven in animal models to prevent restenosis after procedures. It examines current vector and gene transfer techniques for vessel walls, highlighting efficiency as key to success.

Area of Science:

  • Cardiovascular Research
  • Gene Therapy
  • Vascular Biology

Background:

  • Post-interventional restenosis remains a significant clinical challenge.
  • Gene therapy offers a promising approach to prevent vascular remodeling.
  • Effective delivery of genetic material to the vessel wall is crucial.

Purpose of the Study:

  • To review current delivery strategies for vascular gene therapy.
  • To focus on methods demonstrated to limit post-interventional restenosis in vivo.
  • To assess the efficacy of existing vectors and gene transfer techniques.

Main Methods:

  • Literature review of studies utilizing in vivo model systems.
  • Analysis of delivery strategies for vascular gene therapy.
  • Evaluation of vector efficacy and gene transfer methods.

More Related Videos

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium
10:18

In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium

Published on: May 6, 2018

Related Experiment Videos

Last Updated: Jul 25, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium
10:18

In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium

Published on: May 6, 2018

Main Results:

  • Several delivery strategies show potential in limiting restenosis in animal models.
  • Current vectors and methods vary in their efficiency for gene transfer to the vessel wall.
  • In vivo demonstration of efficacy is a critical factor.

Conclusions:

  • Delivery strategy is paramount for successful vascular gene therapy.
  • Further optimization of vectors and methods is needed to improve efficiency.
  • In vivo validation is essential for clinical translation.